MultiCell Technologies Inc (MCET)

[august1991]

The Emmes Group, a strategy consulting firm with offices in Boston and San Francisco, believes if OXIS achieves all of its clinical development milestones, purchases manufacturing rights to the ADCs, and meets worldwide sales and sublicensing expectations following receipt of marketing approval for the three ADCs for the treatment of breast cancer and multiple myeloma, MCIT could expect to receive in excess of $540 million during the term of the agreement.